Fresenius Medical Care's Ogden, Utah plant failed to investigate leaking peritoneal dialysis bags, leading to a 2026 recall.
What happened
FDA inspected the Fresenius USA Manufacturing Ogden Plant in Ogden, Utah, from March 2 to 6, 2026. Investigators found the company had not adequately investigated a trend of 35 customer complaints about leaking Delflex Peritoneal Dialysis Solution bags, rated the risk as property damage rather than peritonitis, and did not recall until April 2026, after the inspection. FDA also found the program for visually inspecting injectable bags was inadequate.
What FDA found
The company did not thoroughly investigate a trend of 35 complaints about leaking Delflex bags and treated the harm as property damage instead of peritonitis, which its own risk matrix had flagged as the highest severity.
21 CFR 211.192Corrective and preventive actions for the leaking bags were not adequate or timely, and the company did not recall the affected lots until April 2026, after FDA's inspection.
21 CFR 211.192The company lacked adequate written production and process control procedures to ensure its drug products had the identity, strength, quality and purity they claimed.
21 CFR 211.100(a)Staff who visually inspected injectable bags were not properly qualified, because the qualification kit's particles were not representative in size and the records lacked enough detail.
21 CFR 211.100(a)
What FDA wants
FDA tells the company to respond in writing within 15 working days describing corrections and preventive actions, including independent root cause assessments, a quality unit remediation plan, a process capability assessment, and a review of printing and leak detection. FDA also says the company should engage a qualified CGMP consultant to audit its operation.
Who should pay attention
- dialysis clinics and providers who stock or administer peritoneal dialysis solutions
- companies that buy finished LVP bags from this contract manufacturer
- drugmakers that rely on visual inspection qualification programs for injectables
This is a summary. Read the original letter on fda.gov.